Thirdly, although our preclinical evidence demonstrated the therapeutic potential of CDK4/6 inhibition CRC CDX and PDX xenograft models, clinical studies are essential to confirm the potentials of abemaciclib and other CDK4/6 inhibitors in CRC. The gene discussed is CDK4; the disease is colorectal carcinoma.